Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia (Q47380672)

15 January 2018

title

Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia (English)

1 reference

15 January 2018

main subject

hypercholesterolemia

0 references

mipomersen parent acid

1 reference

Elisabeth Steinhagen-Thiessen

inferred from title

author

series ordinal

2

object named as

Elisabeth Steinhagen-Thiessen

1 reference

15 January 2018

Carmen Gelsinger

1

1 reference

15 January 2018

Ursula Kassner

series ordinal

3

1 reference

15 January 2018

publication date

1 July 2012

1 reference

15 January 2018

published in

Drugs

1 reference

15 January 2018

volume

72

1 reference

15 January 2018

issue

11

1 reference

15 January 2018

page(s)

1445-1455

1 reference

15 January 2018

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

ESC/EAS Guidelines for the management of dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

NLA Symposium screening and treatment of familial hypercholesterolemia: how can we do better? Opening and introductions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

A systematic review and meta-analysis on the therapeutic equivalence of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Efficacy criteria and cholesterol targets for LDL apheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Antisense apolipoprotein B therapy: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Progress in antisense technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Novel therapies and new targets of treatment for familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Antisense oligonucleotides as therapeutics for hyperlipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Postprandial lipoprotein metabolism and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Recent progress in understanding apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Elucidating cell signaling mechanisms using antisense technology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635060-000000000-00000

Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia

21 January 2018

1 reference

12 December 2020

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

1 reference

12 December 2020

Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL]

1 reference

12 December 2020

"Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/11635060-000000000-00000

Identifiers

DOI

1 reference

15 January 2018

Dimensions Publication ID

1042882373

0 references

1 reference

15 January 2018